Cargando…

Developing an immunotherapy strategy for the effective treatment of patients with squamous cell carcinoma of the head and neck

Detalles Bibliográficos
Autores principales:	Moudgil, Tarsem, Bell, R Bryan, Leidner, Rom, Van de Ven, Rieneke, Feng, Zipei, Affentoulis, Michael, Paustian, Christopher, Dubay, Christopher, Hilton, Traci L, Urba, Walter J, Hu, Hong-Ming, Bifulco, Carlo B, Fox, Bernard A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991341/ http://dx.doi.org/10.1186/2051-1426-1-S1-P262

Ejemplares similares

Characterizing the immunoprofile and endogenous immune response to squamous cell carcinomas of the head and neck to guide development of effective immunotherapy strategies
por: Moudgil, Tarsem, et al.
Publicado: (2014)

An evaluation of autologous tumor-reactive TIL generation from head and neck squamous cell cancers
por: Mougdil, Tarsem, et al.
Publicado: (2015)

Utilizing quantitative immunohistochemistry for relationship analysis of tumor microenvironment of head and neck cancer patients
por: Feng, Zipei, et al.
Publicado: (2014)

Cross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory t cells
por: Ye, Wei, et al.
Publicado: (2014)

Novel strategy to monitor apparent tumor-specific T cells in patients with cancer
por: van de Ven, Rieneke, et al.
Publicado: (2013)

Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC
por: Hilton, Traci, et al.
Publicado: (2014)

Autophagosome-based strategy to monitor apparent tumor-specific CD8 T cells in patients with prostate cancer
por: van de Ven, Rieneke, et al.
Publicado: (2018)

Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC
por: Sanborn, Rachel, et al.
Publicado: (2015)

Adoptive TIL in HPV-negative oral scca
por: Leidner, Rom, et al.
Publicado: (2015)

Assessment of the tumor immune-environment in patients with head and neck cancer
por: Feng, Zipei, et al.
Publicado: (2015)

DPV-001 an autophagosome-enriched cancer vaccine in phase II clinical trials contains 25 putative cancer antigens, DAMPS, HSPS and agonists for TLR 2, 3, 4, 7 and 9
por: Hilton, Traci L, et al.
Publicado: (2013)

An image analysis algorithm based on the hue saturation density transformation, an important tool for melanoma immunotherapy research
por: Dzubay, Jeffrey A, et al.
Publicado: (2014)

Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma
por: Feng, Zipei, et al.
Publicado: (2015)

OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer
por: Montler, Ryan, et al.
Publicado: (2016)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
por: Cohen, Ezra E. W., et al.
Publicado: (2019)

A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer
por: Sanborn, Rachel E., et al.
Publicado: (2017)

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
por: Duhen, Rebekka, et al.
Publicado: (2021)

Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma
por: Leidner, Rom, et al.
Publicado: (2021)

Evaluation of circulating tumor cell gene expression profiles before and following combination immunotherapy for advanced prostate cancer
por: Puri, Sachin, et al.
Publicado: (2014)

The Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: on Subsets and Subsites
por: Wondergem, Niels E., et al.
Publicado: (2020)

Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance
por: Couey, Marcus A., et al.
Publicado: (2019)

OX40 and other immunoregulatory molecules are highly expressed on tumor infiltrating lymphocytes in oral, head and neck squamous cell carcinoma
por: Montler, Ryan, et al.
Publicado: (2014)

Immunotherapy in head and neck squamous cell carcinoma: a narrative review
por: Sharon, Shay, et al.
Publicado: (2022)

Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment
por: Andtbacka, Robert HI, et al.
Publicado: (2015)

Explant Modeling of the Immune Environment of Head and Neck Cancer
por: Sharon, Shay, et al.
Publicado: (2021)

At the Crossroads of Molecular Biology and Immunology: Molecular Pathways for Immunological Targeting of Head and Neck Squamous Cell Carcinoma
por: Wondergem, Niels E., et al.
Publicado: (2021)

Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
por: Falchook, Gerald S., et al.
Publicado: (2016)

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
por: Duhen, Thomas, et al.
Publicado: (2018)

Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes
por: Duhen, Thomas, et al.
Publicado: (2022)

Immunotherapy for head and neck squamous cell carcinoma
por: Fuereder, Thorsten
Publicado: (2016)

Immunotherapy for Head and Neck Squamous Cell Carcinoma
por: Moskovitz, Jessica, et al.
Publicado: (2018)

Immunotherapy in Head and Neck Squamous Cell Cancer
por: Denaro, Nerina, et al.
Publicado: (2018)

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
por: Cavalieri, Stefano, et al.
Publicado: (2021)

Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies
por: Fox, Bernard A., et al.
Publicado: (2023)

The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches
por: Economopoulou, Panagiota, et al.
Publicado: (2017)

Correction: STING expression and response to treatment with STING ligands in premalignant and malignant disease
por: Baird, Jason R., et al.
Publicado: (2018)

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021)

Editorial: Mechanisms of Lymphocyte Exclusion in the Tumor Microenvironment
por: van de Ven, Rieneke, et al.
Publicado: (2022)

Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer
por: Bell, R. Bryan, et al.
Publicado: (2022)

Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma
por: Qi, Xinmeng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7dnq1nhra1eapk46nnuc4g5viu